Lead asset is a TEAD1 inhibitor IK-930 targeting the HIPPO pathway. It works through disruption of the link between transcriptional enhancer activator domain (TEAD') and its co-activator ...
As healthcare becomes more entrenched in the digital revolution, the need for an approved set of protocols for care delivery — clinical pathways — is becoming increasingly critical. Clinical pathways, ...
CHICAGO--(BUSINESS WIRE)--Syntellis Performance Solutions, the leading provider of enterprise performance management software, data and intelligence solutions, today announced the launch of Focus ...